Cited by 185Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesAttention Deficit Hyperactivity Disorder

Citalopram, Methylphenidate, or Their Combination in Geriatric Depression: A Randomized, Double-Blind, Placebo-Controlled Trial

Open access
Lavretsky, Helen, Reinlieb, Michelle, St. Cyr, Natalie, Siddarth, Prabha, Ercoli, Linda M., Senturk, Damla·2015·American Journal of Psychiatry

Abstract

OBJECTIVE: The authors evaluated the potential of methylphenidate to improve antidepressant response to citalopram, as assessed by clinical and cognitive outcomes, in elderly depressed patients. METHOD: The authors conducted a 16-week randomized double-blind placebo-controlled trial for geriatric depression in 143 older outpatients diagnosed with major depression comparing treatment response in three treatment groups: methylphenidate plus placebo (N=48), citalopram plus placebo (N=48), and citalopram plus methylphenidate (N=47). The primary outcome measure was change in depression severity. Remission was defined as a score of 6 or less on the Hamilton Depression Rating Scale. Secondary outcomes included measures of anxiety, apathy, quality of life, and cognition. RESULTS: Daily doses ranged from 20 mg to 60 mg for citalopram (mean=32 mg) and from 5 mg to 40 mg for methylphenidate (mean=16 mg). All groups showed significant improvement in depression severity and in cognitive performance. However, the improvement in depression severity and the Clinical Global Impressions improvement score was more prominent in the citalopram plus methylphenidate group compared with the other two groups. Additionally, the rate of improvement in the citalopram plus methylphenidate group was significantly higher than that in the citalopram plus placebo group in the first 4 weeks of the trial. The groups did not differ in cognitive improvement or number of side effects. CONCLUSIONS: Combined treatment with citalopram and methylphenidate demonstrated an enhanced clinical response profile in mood and well-being, as well as a higher rate of remission, compared with either drug alone. All treatments led to an improvement in cognitive functioning, although augmentation with methylphenidate did not offer additional benefits.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2014.14070889

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Combination of citalopram and methylphenidate may improve mood and well-being in LLD.

    “Combination of citalopram and methylphenidate may improve mood and well-being and lead to a higher remission rate of LLD compared to either drug alone133.”

    From Mechanisms and treatment of late-life depression (2019) · cites this paper as [133]

  • Combination of citalopram and methylphenidate may lead to a higher remission rate of LLD compared to either drug alone.

    “Combination of citalopram and methylphenidate may improve mood and well-being and lead to a higher remission rate of LLD compared to either drug alone133.”

    From Mechanisms and treatment of late-life depression (2019) · cites this paper as [133]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [29]Lezak MD Howieson DB Loring DW Neuropsychological Assessment 4 New York Oxford 2004

Cited by

Sorted by citations

Authors
Lavretsky, H., Reinlieb, M., St. Cyr, N., Siddarth, P., Ercoli, L. M., & Senturk, D.
Affiliations
  • University of California, Los Angeles (US)
  • From the UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles; the Department of Psychiatry, UCLA School of Medicine, Los Angeles; and the Departments of Biostatistics and Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles.
Venue
American Journal of Psychiatry
Published
2015-06-01
Volume
172
Issue
6
Pages
561-569
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2036375653
Cited by
184
References
47
Citations by year
2026: 5 · 2025: 6 · 2024: 14 · 2023: 13 · 2022: 17 · 2021: 34 · 2020: 18 · 2019: 18 · 2018: 12 · 2017: 20 · 2016: 17 · 2015: 10
FWCI
14.14
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (MH086481, K24MH086481, R01MH077650, MH077650)
  • Jonsson Comprehensive Cancer Center
  • Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
geriatric depression, citalopram, methylphenidate, antidepressant augmentation, combination therapy, depression remission, cognitive function, anxiety, apathy, quality of life, antidepressant side effects
MeSH terms
Aged, Anxiety Disorders, Cognition Disorders, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Methylphenidate, Middle Aged, Personality Assessment, Psychometrics, Quality of Life, Citalopram, Apathy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review